Get the Stockscreener App
21.77
4.68%
-1.07
After Hours:
21.70
-0.07
-0.32%
Janux Therapeutics Inc stock is traded at $21.77, with a volume of 643.69K.
It is down -4.68% in the last 24 hours and down -5.39% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$22.84
Open:
$22.5
24h Volume:
643.69K
Relative Volume:
0.83
Market Cap:
$1.31B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-12.09
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
-10.78%
1M Performance:
-5.39%
6M Performance:
-29.39%
1Y Performance:
-54.54%
1-Day Range:
$21.73
$22.86
1-Week Range:
$21.73
$24.54
52-Week Range:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
21.77 | 1.37B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics stock hits 52-week low at 21.97 USD - Investing.com
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at Barclays - MarketBeat
Top 5 Oncology Stocks to Watch According to Barclays By Investing.com - Investing.com Canada
Janux Therapeutics (NASDAQ:JANX) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Shares Gap UpTime to Buy? - MarketBeat
Institution Moves: Will Denison Mines Corp stock benefit from M A2025 Earnings Impact & Real-Time Chart Pattern Alerts - خودرو بانک
Janux Therapeutics Announces Departure of Chief Strategy Officer - The Globe and Mail
Janux Therapeutics chief strategy officer departs in company-initiated move By Investing.com - Investing.com Nigeria
Janux Therapeutics chief strategy officer departs in company-initiated move - Investing.com
Big Money Moves: Is Janux Therapeutics Inc. stock a buy or sell2025 Analyst Calls & Technical Pattern Based Signals - khodrobank.com
Janux Therapeutics, Inc. $JANX Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Momentum Shift: Is MGRM forming bullish engulfing patternsCEO Change & Free Expert Verified Stock Movement Alerts - khodrobank.com
Aug Closing: Can Janux Therapeutics Inc generate free cash flowPortfolio Return Report & Real-Time Stock Entry Alerts - khodrobank.com
US Market Wrap: Whats the fair value of Achieve Life Sciences Inc stockChart Signals & Smart Investment Allocation Tips - khodrobank.com
Aug Ideas: Is NetApp Inc subject to activist investor interestQuarterly Trade Review & Weekly Watchlist for Consistent Profits - خودرو بانک
Investment Review: What is Janux Therapeutics Incs valuation compared to sectorOil Prices & Free Verified High Yield Trade Plans - خودرو بانک
Momentum Shift: Should you avoid CBFV stock right nowMarket Performance Report & Risk Controlled Swing Trade Alerts - خودرو بانک
Barclays Initiates Coverage on JANX with Overweight Rating | JAN - GuruFocus
Barclays Initiates Coverage of Janux Therapeutics (JANX) with Overweight Recommendation - Nasdaq
Bernstein Initiates Janux Therapeutics at Overweight With $47 Price Target - MarketScreener
Janux Therapeutics initiated with an Overweight at Barclays - TipRanks
Highs Report: Is HCKT forming bullish engulfing patternsMarket Trend Report & Expert Verified Movement Alerts - خودرو بانک
Aug Swings: Should I hold or sell INNOVATE Corp. Equity Right now2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - khodrobank.com
Market Fear: What is Janux Therapeutics Incs valuation compared to sectorWeekly Risk Summary & AI Powered Trade Plan Recommendations - خودرو بانک
Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT - Yahoo Finance
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at Truist Financial - MarketBeat
Woodline Partners LP Has $39.34 Million Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics Inc. recovery potential after sell off2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Analyzing recovery setups for Janux Therapeutics Inc. investorsWeekly Risk Report & Fast Exit Strategy with Risk Control - newser.com
Statistical indicators supporting Janux Therapeutics Inc.’s strengthTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
Visualizing Janux Therapeutics Inc. stock with heatmaps2025 Price Targets & Smart Money Movement Alerts - newser.com
Comparing Janux Therapeutics Inc. in custom built stock radars2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockExit Point & Weekly Momentum Picks - newser.com
10 Best Up and Coming Stocks with Huge Upside Potential - Insider Monkey
Institutional scanner results for Janux Therapeutics Inc.Market Risk Analysis & High Conviction Investment Ideas - newser.com
Short interest data insights for Janux Therapeutics Inc.Take Profit & Intraday High Probability Setup Alerts - Newser
Cubist Systematic Strategies LLC Has $2.05 Million Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Bank of America Securities Remains a Buy on Janux Therapeutics Inc (JANX) - The Globe and Mail
Possible Bearish Signals With Janux Therapeutics Insiders Disposing Stock - 富途牛牛
Stifel Nicolaus Reaffirms “Buy” Rating for Janux Therapeutics (NASDAQ:JANX) - Defense World
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at Guggenheim - MarketBeat
Alyeska Investment Group L.P. Purchases 63,762 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ) - Seeking Alpha
Truist Initiates Janux Therapeutics at Buy With $100 Price Target - MarketScreener
Janux Therapeutics initiated with a Buy at Truist - TipRanks
Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements - TipRanks
Janux Therapeutics resumed with a Buy at Stifel - TipRanks
Stifel resumes Janux Therapeutics stock coverage with Buy rating By Investing.com - Investing.com Canada
Walleye Capital LLC Makes New Investment in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $86.90 - MarketBeat
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):